In addition, targeting STAT3 can control abnormal metabolic conditions such as diabetes and obesity, which might reduce the risk of cancer associated with those conditions [34, 45]. The gene discussed is STAT3; the disease is obesity due to melanocortin 4 receptor deficiency.